Publication:
Clinical Pharmacokinetics of Antimalarial Drugs

dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.otherNuffield Department of Clinical Medicineen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherLiverpool School of Tropical Medicineen_US
dc.contributor.otherHarborview Medical Centeren_US
dc.date.accessioned2018-10-12T07:52:08Z
dc.date.available2018-10-12T07:52:08Z
dc.date.issued1985-01-01en_US
dc.description.abstractFor the past 300 years antimalarial dosage regimens have not been based on pharmacokinetk information. However, now that this information is available, it is appropriate to examine current recommendations for prophylaxis and treatment. In healthy subjects, the cinchona alkaloids (quinine and quinidine), primaquine and proguanil (chloroguanide) are all rapidly eliminated with half-lives (t½β) of between 6 and 12 hours. Hepatic biotransformation accounts for approximately 80, 96 and 50% of their total clearance, respectively. In malaria, the pharmacokinetic properties of quinine and quinidine are significantly altered with a decrease in the apparent volume of distribution (Vd), prolongation of the elimination half-life, and a reduction in systemic clearance (CL) that is proportional to the severity of infection. Red cell concentrations and plasma protein binding are both increased in severe disease. Parenteral quinine or quinidine should be given by slow intravenous infusion rather titan by intravenous or intramuscular injection, and a loading dose is necessary in severe infections. Chloroquine (t½β 6 to 50 days) and mefloquine (t½β 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose. Both drugs are concentrated in erythrocytes and 55% of chloroquine and 98% of mefloquine in plasma is bound to protein. The pharmacokinetics of chloroquine are complex and, because of the extremely long β phase, difficult to accurately define. Pyrimethamine (t½ 35 to 175 hours) has more limited tissue distribution, plasma and erythrocyte concentrations are similar, and 85% of the drug in plasma is bound to plasma proteins. The clearance of quinine, mefloquine and pyrimethamine appears to be higher in children than in adults. Currently, most of the information available on disposition of antimalarial drugs in humans is derived from studies in healthy adult subjects. More information is required on their pharmacokinetics in malaria, pregnancy, and in young children. © 1985, ADIS Press Limited. All rights reserved.en_US
dc.identifier.citationClinical Pharmacokinetics. Vol.10, No.3 (1985), 187-215en_US
dc.identifier.doi10.2165/00003088-198510030-00001en_US
dc.identifier.issn11791926en_US
dc.identifier.issn03125963en_US
dc.identifier.other2-s2.0-0021985855en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/30902
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0021985855&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleClinical Pharmacokinetics of Antimalarial Drugsen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0021985855&origin=inwarden_US

Files

Collections